Ciab is for people who don’t benefit from this combination and there are many of them. So renoxo won’t replace ciab.
The side effects of the renoxo combination are horrible.
If those combos have already failed for a patient they will surely prefer a side effect free treatment like ciab. They are already very ill.
The triggering by ciab is right by the tumor whereas renoxo will be pancreas wide. So ciab is more targeted and less destructive of other dividing cells.
I think in late stage inoperable ciab still has many advantages over renoxo.
There may be more patients with less side effects because of the renoxo delivery but overall it’s still not as gentle or site specific as ciab.
And renoxo has no upside with ascites or diabetes or cabbinoids does it?
Also how do you make money from renoxo as it’s difficult to commercialize. Where’s the patent that can protect an already established way of delivery?
News 
Market Data 
Discover 
